Panel: CDMO Strategic Inflection Point: From Capacity Provider to Innovation Architect

The CDMO industry has reached a strategic inflection point where competitive advantage no longer comes from simply offering capacity or geographic reach. Success is now defined by three converging forces: selective partnership models, execution excellence in complex modalities, and digital manufacturing readiness. This panel brings together CDMO leaders to discuss how they're repositioning their organizations as innovation architects who co-create manufacturing solutions with pharma partners.

Key Discussion Points:

- Strategic selectivity and partnership evolution: How CDMOs are choosing projects that align with core capabilities and positioning themselves as strategic partners rather than overflow capacity in an era of pharma consolidation

- Execution excellence as competitive moat: Investing in quality systems, regulatory readiness, and tech transfer efficiency to differentiate in a market where access to the right capacity—not just any capacity—determines success

- Digital manufacturing deployment: Moving AI-driven quality monitoring, digital twins, and predictive analytics from pilot projects to production-scale implementation that delivers measurable ROI and meets pharma partners' demands for real-time visibility